Miller Investment Management LP Sells 4,197 Shares of VanEck Biotech ETF (NASDAQ:BBH)

Miller Investment Management LP cut its holdings in VanEck Biotech ETF (NASDAQ:BBH) by 4.0% in the third quarter, HoldingsChannel reports. The firm owned 99,813 shares of the company’s stock after selling 4,197 shares during the quarter. VanEck Biotech ETF accounts for 1.8% of Miller Investment Management LP’s portfolio, making the stock its 13th largest position. Miller Investment Management LP’s holdings in VanEck Biotech ETF were worth $17,706,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Truvestments Capital LLC purchased a new position in shares of VanEck Biotech ETF in the 3rd quarter worth $44,000. Mather Group LLC. purchased a new position in VanEck Biotech ETF in the second quarter worth about $46,000. Red Lighthouse Investment Management LLC bought a new stake in VanEck Biotech ETF during the second quarter worth approximately $51,000. FSA Wealth Management LLC purchased a new stake in VanEck Biotech ETF during the third quarter valued at approximately $54,000. Finally, Coastline Trust Co bought a new stake in shares of VanEck Biotech ETF in the 3rd quarter valued at approximately $59,000. Institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Trading Down 1.0 %

Shares of VanEck Biotech ETF stock opened at $165.13 on Wednesday. The stock has a 50 day moving average price of $171.23 and a 200-day moving average price of $173.15. VanEck Biotech ETF has a one year low of $151.35 and a one year high of $183.64.

VanEck Biotech ETF Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.